Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ESG401 vs investigator’s choice chemotherapy in HR+/HER2- advanced or metastatic breast cancer
CTR20241439Phase 3Suspended
- Sponsor
- Affinity Biopharma
- Start
- Jul 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of ESG401 in breast cancer, sponsored by Affinity Biopharma. Started Jul 2024; status: suspended.
02
Drugs
ESG401
03
Conditions
breast cancer
Beyond the preview
Go deeper on CTR20241439.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20241439.